AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 TGS, 152 RNA-Seq, 67 SNP Arrays), we found a driver role for GATA1 and MEN1 somatic mutations. Metastases were enriched in ESR1, PTEN, CDH1, PIK3CA and RB1 mutations; MDM4, MYC amplifications; ARID1A deletions. An increase in clonality was observed in driver genes like ERBB2 and RB1. Intrinsic subtype switching occurred in 36% of cases. Luminal A/B to HER2-Enriched switching was associated with TP53 and/or PIK3CA mutations. Metastases had lower immune score and increased immune permissive cells. High TMB correlated to shorter time to relapse in HR+/HER2- cancers. ESCAT tier I/II alterations were detected in 51% of patients and matched therapy was used in 7%. Integration of multi-omics analyses in clinical practice could impact treatment strategies in MBC.

Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative / P. Aftimos, M. Oliveira, A. Irrthum, D. Fumagalli, C. Sotiriou, E. Nili Gal-Yam, M.E. Robson, J. Ndozeng, A. Di Leo, E.M. Ciruelos, E. de Azambuja, G. Viale, E.D. Scheepers, G. Curigliano, J.M. Bliss, J.S. Reis-Filho, M. Colleoni, M. Balic, F. Cardoso, J. Albanell, C. Duhem, S. Marreaud, D. Romagnoli, B. Rojas, A. Gombos, H. Wildiers, A. Guerrero-Zotano, P. Hall, A. Bonetti, K.F. Larsson, M. Degiorgis, S. Khodaverdi, R. Greil, A. Sverrisdottir, M. Paoli, E. Seyll, S. Loibl, B. Linderholm, G. Zoppoli, N.E. Davidson, O.T. Johannsson, P.L. Bedard, S. Loi, S. Knox, D.A. Cameron, N. Harbeck, M. Lasa Montoya, M. Brandão, A. Vingiani, C. Caballero, F.S. Hilbers, L.R. Yates, M. Benelli, D. Venet, M.J. Piccart. - In: CANCER DISCOVERY. - ISSN 2159-8274. - (2021). [Epub ahead of print] [10.1158/2159-8290.CD-20-1647]

Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative

D. Fumagalli;G. Viale;G. Curigliano
Conceptualization
;
M. Colleoni;A. Vingiani;
2021

Abstract

AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 TGS, 152 RNA-Seq, 67 SNP Arrays), we found a driver role for GATA1 and MEN1 somatic mutations. Metastases were enriched in ESR1, PTEN, CDH1, PIK3CA and RB1 mutations; MDM4, MYC amplifications; ARID1A deletions. An increase in clonality was observed in driver genes like ERBB2 and RB1. Intrinsic subtype switching occurred in 36% of cases. Luminal A/B to HER2-Enriched switching was associated with TP53 and/or PIK3CA mutations. Metastases had lower immune score and increased immune permissive cells. High TMB correlated to shorter time to relapse in HR+/HER2- cancers. ESCAT tier I/II alterations were detected in 51% of patients and matched therapy was used in 7%. Integration of multi-omics analyses in clinical practice could impact treatment strategies in MBC.
Settore MED/06 - Oncologia Medica
28-giu-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
AURORA Proofs.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 5.57 MB
Formato Adobe PDF
5.57 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/854512
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 17
social impact